Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

By S. Loi, Benjamin Haibe-Kains, C. Desmedt, F. Lallemand, A. Tutt, Cheryl Gillet, P. Ellis, Adrian L. Harris, J. Bergh, John A. Foekens and 7 more. Journal of Clinical Oncology, 2007

829 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/5e40a9cc3bb6dadfff78b55defdf92cba209b58a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients (2010, neutral): “2 82 [29] GSE5327 GPL96 0(0%) NA 11(19%) 6.”
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer (2010, positive): “Gene expression analysis using Affymetrix U133A Genechips (Affymetrix) was performed and normalized as previously described (3).”
Biological determinants of endocrine resistance in breast cancer (2009, result): “Because of their shared biological features, many of the signatures selected on the basis of correlations with outcome are largely concordant , both with each other and with more generally derived prognostic signatures that have not been tested for association with response to tamoxifen, for exampl”
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer (2011, methodology): “Finally, expression of KLK5 and KRT6B was inversely proportional to vimentin in normal tissue both in vitro and in vivo, whereas there was a positive correlation between vimentin and KRT6B in the cancer samples.”
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “There are other published gene expression signatures that are less known, such as the wound-response or healing model,(11) the twogene expression ratio (HOXB13:IL17BR),(12) the Rotterdam 76 gene signature,(13,14) and the genomic grade index (also known as MapQuant Dx).(15,16) The little or virtually”
Triple-negative breast cancer--current status and future directions. (2009, background): “Recently, a multigene index representing a genomic correlate genomic grade index (GGI) of histological tumor grade has been established [96, 97].”
GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, neutral): “GSA-Tumor allows division of the 1881-sample data set into five major subgroups based on clinical annotations available from GEO [13]; 1) all 1881 tumors, 2) ER-positive tumors (n=1225), 3) ER-negative tumors (n=395), 4) systemically untreated patients (n=927), and 5) patients treated with tamoxifen”
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome (2011, methodology): “[56], although it included ,30% more patients.”
Supervised risk predictor of breast cancer based on intrinsic subtypes. (2009, background): “Table 2 shows the multivariable analyses of these models in an independent cohort of untreated patients.(7,13-15) In model A, subtypes, tumor size (T1 v greater), and histologic grade were found to be significant factors for ROR.”
Artificial intelligence as the next step towards precision pathology (2020, background): “Mitosis detection has been also in focus in research [49].”
A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates (2012, methodology): “4 Examples It has been known that the breast cancer can be classified into different subtypes using gene expression profile and the effective treatment may be different for different subtypes of the disease [Loi et al., 2007]. In this section, we apply the proposed method to study the potential inte”